Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9928911 | 1.00 | HRH2 (0.31) | — | |
| SCHEMBL1488954 | 0.98 | — | — | |
| Hydrochloric Acid SCHEMBL3009055 | 0.86 | HRH4 (0.31) | — | |
| SCHEMBL5663768 | 0.82 | HRH3 (0.34) | — | |
| SCHEMBL4671779 | 0.82 | — | — | |
| SCHEMBL8894634 | 0.80 | HRH1 (0.36) | — | |
| Hydrochloric Acid SCHEMBL7440333 | 0.80 | — | — | |
| Hydrochloric Acid SCHEMBL13718807 | 0.80 | — | — | |
| SCHEMBL3872946 | 0.77 | ALDH1A1 (0.33) | — | |
| SCHEMBL2705361 | 0.77 | L3MBTL1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3294739-B1 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2019-07-31 | — | — | EP | disclosed |
| EP-3294739-A1 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | Bristol-Myers Squibb Company (US) | 2018-03-21 | — | — | EP | disclosed |
| US-9725449-B2 | Tricyclic compounds as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-08 | — | — | US | disclosed |
| WO-2016183118-A1 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-11-17 | — | — | WO | disclosed |
| US-20160333013-A1 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2016-11-17 | — | — | US | disclosed |
| US-8846736-B2 | Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents | N30 PHARMACEUTICALS, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140194481-A1 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents | N30 PHARMACEUTICALS, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20130253024-A1 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents | N30 PHARMACEUTICALS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-8470857-B2 | Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents | N30 PHARMACEUTICALS, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20110136881-A1 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents | N30 PHARMACEUTICALS, LLC (US) | 2011-06-09 | — | — | US | disclosed |
| US-5414013-A | Enzyme inhibitors | E. R. SQUIBB & SONS, INC. (US) | 1995-05-09 | — | — | US | disclosed |
| US-5414017-A | Cardiovascular agents | E. R. SQUIBB & SONS, INC. (US) | 1995-05-09 | — | — | US | disclosed |
| EP-0449523-B1 | Mercapto- or acylthio-trifluoromethyl amide derivatives and their use | SQUIBB & SONS INC (US) | 1994-08-17 | — | — | EP | disclosed |
| US-5223516-A | Endopeptidase inhibitors | E. R. SQUIBB & SONS, INC. (US) | 1993-06-29 | — | — | US | disclosed |
| EP-0449523-A1 | Mercapto- or acylthio-trifluoromethyl amide derivatives and their use | E.R. SQUIBB & SONS, INC. (US) | 1991-10-02 | — | — | EP | disclosed |